Press Releases

    • SEP 15 2016

    Oncotarget Article Describes Development of Imipridone ONC201

    Philadelphia, PA (September 15, 2016) – Oncoceutics, Inc. announced the publication of a review article in the journal Oncotarget entitled “Discovery and clinical introduction of first-in-class imipridone ONC201.” The article summarizes the history of how the molecule was discovered, its mechanism of action, and its preclinical profile, as well as its move into the clinic

    • SEP 08 2016

    ONC201 Continues to Show Excellent Safety When Dosed Weekly

    Philadelphia, PA (September 8, 2016) – Oncoceutics, Inc. announced the successful completion of the dose escalation phase of a clinical trial for the company’s lead molecule ONC201 using weekly dosing.  Oncoceutics has previously reported the exceptional safety profile for ONC201 in multiple clinical trials using a dosing regimen of once every three weeks. The weekly

    • AUG 16 2016

    Oncoceutics Awarded FDA Orphan Grant for ONC201 Multiple Myeloma Trial

    Philadelphia, PA (August 16, 2016) – Oncoceutics announced that it has been awarded an orphan grant from the U.S. Food and Drug Administration (FDA) to evaluate its lead molecule, ONC201, a selective antagonist of DRD2 that belongs to the superfamily of G protein-coupled receptors (GPCRs), in a multiple myeloma clinical trial. The award totals $1.7

    • AUG 09 2016

    ONC201 Leads Oncoceutics to New Imipridone Class of Cancer Drugs

    Philadelphia, PA (August 9, 2016) – Oncoceutics, Inc. announced that its initial discovery of ONC201, a benzyl-benzylmethyl-imipridone that has demonstrated excellent anti-cancer activity and safety in preclinical models and ongoing clinical trials, has led to the creation of a new family of chemically-related small molecules that also possess significant anti-cancer activities. The family, which the